CMV-specific T cell therapy - Cell Medica

Drug Profile

CMV-specific T cell therapy - Cell Medica

Alternative Names: Cytovir CMV; Immunoprophylactic adoptive cell therapy - Cell Medica; IMPACT - Cell Medica

Latest Information Update: 01 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Baylor College of Medicine; Fred Hutchinson Cancer Research Center; University College London; University of Birmingham
  • Developer Cell Medica
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cytomegalovirus infections

Most Recent Events

  • 11 May 2015 Stage cell therapeutics has been acquired by Juno Therapeutics
  • 05 Jul 2013 Cell Medica completes the CMV-ACE/ASPECT trial for Cytomegalovirus infections (prevention of recurrence) in United Kingdom (NCT01220895)
  • 01 Jun 2010 CMV-specific T-cell therapy is still in phase III trials for Cytomegalovirus Infections in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top